Journal of Clinical and Experimental Hematopathology最新文献

{"title":"A case of classic Hodgkin lymphoma arising after remission of methotrexate-associated follicular lymphoma.","authors":"Yayoi Ueda, Takehiro Tanaka, Shoji Asakura, Tomofumi Yano","doi":"10.3960/jslrt.23016","DOIUrl":"10.3960/jslrt.23016","url":null,"abstract":"<p><p>Here we describe our experience with a rare case of methotrexate (MTX)-associated lymphoproliferative disorder (LPD) initially diagnosed as follicular lymphoma (FL) and then in relapse as classic Hodgkin lymphoma (CHL). A 66-year-old man was admitted to the hospital with fever and abdominal and lower back pain after a transient remission of MTX-associated FL (MTX-FL) following MTX withdrawal. Computed tomography (CT) showed para-aortic lymphadenopathy, which was compatible with one of the previous FL lesions. We considered a relapse of FL and started bendamustine and rituximab. Although his initial symptoms and para-aortic lymphadenopathy regressed after the first course, he began to have dorsal pain, and multiple osteolytic lesions were detected on CT. We biopsied a Th4 vertebra osteolytic lesion, and the results indicated MTX-associated CHL (MTX-CHL). We successfully treated advanced MTX-CHL with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD). This case suggests the importance of repeat biopsy of a new lesion arising after resolution of previously affected sites in MTX-LPD and the effectiveness of A+AVD in treating advanced MTX-CHL.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9899815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study.","authors":"Masuho Saburi, Kazuki Okuhiro, Natsumi Yoshida, Takami Haruyama, Yui Moroga, Yuka Yanai, Kazuhito Itani, Kuniko Takano, Shuhei Honda, Keiji Ono, Manami Iwanaga, Hitohiro Sasaki, Miyuki Abe, Kazuhiro Kohno, Toshiyuki Nakayama, Eiichi Ohtsuka, Masao Ogata","doi":"10.3960/jslrt.23015","DOIUrl":"10.3960/jslrt.23015","url":null,"abstract":"), and PFS were compared between the BR and GB groups. Tumor volume was determined according to the Groupe d’Étude des Lymphomes Folliculaires (GELF) criteria, and response was determined according to the International Workshop to standardize response criteria for NHL, 9 using computed tomography (CT) or 18 F-fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT). Adverse events including febrile neutropenia, sepsis, pneumonia, herpes zoster, and cytomegalovirus (CMV) infection, were evaluated by CTCAE Ver5.0. Survival was analyzed starting from the date of treatment initiation. PFS was defined as the period from treatment to dis - ease progression, relapse, or death. The cumulative incidence of CMV infection was analyzed using Gray’s test, and the competing events were deaths due to causes other than infection. All statistical analyses were performed with EZR software. 10 This study was approved by the ethics review board of Oita Prefectural Hospital, and by the ethics review board of each collaborating research institution. Patients’ informed consent was obtained in the form of opt-out on a","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Follicular lymphoma microenvironment: insights provided by single-cell analysis.","authors":"Yoshiaki Abe","doi":"10.3960/jslrt.23012","DOIUrl":"10.3960/jslrt.23012","url":null,"abstract":"<p><p>Follicular lymphoma (FL) is the most frequent indolent lymphoma and is characterized by the abundant infiltration of tumor microenvironment (TME) cells. The activity of TME cells reportedly plays an important role in the biology of FL. TME cells that reside within neoplastic follicles, such as T-follicular helper cells and follicular dendritic cells, have been shown to aid in FL development and progression through interactions with malignant B cells, whereas regulatory T cells have unexpectedly shown an apparently favorable prognostic impact in FL. Unfortunately, the understanding of the FL TME, particularly regarding minor cell subsets, has been hampered by unknown cell heterogeneity. As with other solid and hematologic cancers, novel single-cell analysis technologies have recently been applied to FL research and have uncovered previously unrecognized heterogeneities, not only in malignant B cells but also in TME cells. These reports have greatly increased the resolution of our understanding of the FL TME and, at the same time, raised questions about newly identified TME cells. This review provides an overview of the unique aspects of FL TME cells with a clinical viewpoint and highlights recent discoveries from single-cell analysis, while also suggesting potential future directions.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10084431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration.","authors":"Takashi Oyama, Megumi Yasunaga, Masahiro Jona, Masako Nishikawa, Yutaka Yatomi, Akira Honda, Hiroaki Maki, Ken Morita, Yosuke Masamoto, Mineo Kurokawa","doi":"10.3960/jslrt.23023","DOIUrl":"10.3960/jslrt.23023","url":null,"abstract":"<p><p>Thrombocytopenia is a frequent complication in chronic lymphocytic leukemia (CLL). Differentiating autoimmune thrombocytopenia from thrombocytopenia due to bone marrow infiltration is necessary for appropriate treatment, but sometimes difficult. Here we report a 60-year-old male patient with CLL who had achieved complete response after treatment with fludarabine, cyclophosphamide, and rituximab two years prior to presentation. He was admitted with severe thrombocytopenia that was unresponsive to intravenous immunoglobulin. Imaging studies revealed systemic enlarged lymph nodes and bone marrow aspiration was hypercellular with > 95% lymphocytes and scant megakaryocytes. Acalabrutinib 200 mg/day was administered for the treatment of CLL exacerbation. A gradual decrease in CLL cells and recovery of megakaryocytes in bone marrow were observed, but platelet counts remained low. Systemic administration of prednisolone 0.5 mg/kg, in addition to acalabrutinib, was started, considering the contribution of autoimmune thrombocytopenia; platelet recovery was rapid and sustained for more than a year. Even if bone marrow examination suggested thrombocytopenia due to direct leukemic infiltration, it is difficult to exclude the possibility of concomitant immunogenic thrombocytopenia. We conclude that for CLL patients with severe thrombocytopenia, repeating bone marrow examination and concurrent immunosuppressive therapies and treatment of the underlying CLL may be beneficial.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10074960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pathobiology of follicular lymphoma.","authors":"Joaquim Carreras","doi":"10.3960/jslrt.23014","DOIUrl":"10.3960/jslrt.23014","url":null,"abstract":"<p><p>Follicular lymphoma is one of the most frequent lymphomas. Histologically, it is characterized by a follicular (nodular) growth pattern of centrocytes and centroblasts; mixed with variable immune microenvironment cells. Clinically, it is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. It is biologically and clinically heterogeneous. In most patients it is indolent, but others have a more aggressive evolution with relapses; and transformation to diffuse large B-cell lymphoma. Tumorigenesis includes an asymptomatic preclinical phase in which premalignant B-lymphocytes with the t(14;18) chromosomal translocation acquire additional genetic alterations in the germinal centers, and clonal evolution occurs, although not all the cells progress to the tumor stage. This manuscript reviews the pathobiology and clinicopathological characteristics of follicular lymphoma. It includes a description of the physiology of the germinal center, the genetic alterations of BCL2 and BCL6, the mutational profile, the immune checkpoint, precision medicine, and highlights in the lymphoma classification. In addition, a comment and review on artificial intelligence and machine (deep) learning are made.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kikuchi-Fujimoto disease following COVID-19 in a 32-year-old woman.","authors":"Rin Yamada, Yoshihiro Komohara, Hiroshi Yoshii","doi":"10.3960/jslrt.23022","DOIUrl":"10.3960/jslrt.23022","url":null,"abstract":"not associated with COVID-19, with the exception of three cases showing uncommon complications, including heart involvement, generalized lymphade-nopathies, and multisystem inflammatory syndrome. 7,8,10 All but two cases showed complete resolution of clinical symptoms. In one case, cardiac function remained reduced, although whether the heart involvement was associated with KFD or COVID-19 remained unclear. 7 In another case, the clinical course was not documented. 12 Viral particles have never been identified ultrastructurally in the lymph nodes of patients with KFD. The present case and a previous case also did not demonstrate SARS-CoV-2 immunohistochemically. 5 Differential diagnoses for patients with cervical lymph-adenopathy following COVID-19 should include KFD to avoid unnecessary therapeutic interventions, particularly in patients under 40 years old. Further study regarding the relationship between KFD and COVID-19 is necessary.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.","authors":"Masuho Saburi, Masanori Sakata, Yousuke Kodama, Keiichi Uraisami, Hiroyuki Takata, Yasuhiko Miyazaki, Junpei Wada, Shogo Urabe, Eiichi Ohtsuka","doi":"10.3960/jslrt.23017","DOIUrl":"10.3960/jslrt.23017","url":null,"abstract":"","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases.","authors":"Ayumi Sugitani, Suguru Fukuhara, Maki Shibata, Ryosuke Ichihara, Haruhi Furukawa, Akiko Miyagi Maeshima","doi":"10.3960/jslrt.23020","DOIUrl":"10.3960/jslrt.23020","url":null,"abstract":"<p><p>We report two cases of diffuse large B-cell lymphoma (DLBCL) with composite germinal center B-cell (GCB) and non-GCB types. Case 1 was a 72-year-old woman with inguinal lymph node swelling. Two morphologically different lesions were concurrently observed in needle biopsy specimens. One lesion was DLBCL with centroblastic morphology and a GCB phenotype (CD10⁺, BCL6⁺, and MUM1^-), according to the Hans algorithm. The other lesion was DLBCL with anaplastic morphology and a non-GCB phenotype (CD10^-, BCL6⁺, and MUM1⁺). Considering cellular atypia, the GCB-type DLBCL likely progressed to non-GCB-type DLBCL. Case 2 was a 34-year-old man who underwent ileocecal resection, with four lesions observed in the ileum. All four lesions indicated centroblastic morphology. Three lesions showed a GCB phenotype (CD10⁺, BCL6⁺, and MUM1⁺), while the other showed a non-GCB phenotype (CD10^-, BCL6⁺, and MUM1⁺). These tumors were clonally related. BCL2 expression and MYC rearrangement were not related to changes in the cell of origin (COO) in either case. In conclusion, changes in the COO in DLBCL may not be uncommon. Therefore, investigation of the COO in other sites or at relapse may be needed if new drugs with different indications for each COO are developed.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9899816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma.","authors":"Takahiro Haeno,&nbsp;Shinya Rai,&nbsp;Yoshiaki Miyake,&nbsp;Maiko Inoue,&nbsp;Ko Fujimoto,&nbsp;Aki Fujii,&nbsp;Yoshio Iwata,&nbsp;Shuji Minamoto,&nbsp;Takahide Taniguchi,&nbsp;Hiroaki Kakutani,&nbsp;Hiroaki Inoue,&nbsp;Takahiro Kumode,&nbsp;Kentaro Serizawa,&nbsp;Yasuhiro Taniguchi,&nbsp;Chikara Hirase,&nbsp;Yasuyoshi Morita,&nbsp;Hirokazu Tanaka,&nbsp;Yoichi Tatsumi,&nbsp;Takashi Ashida,&nbsp;Itaru Matsumura","doi":"10.3960/jslrt.23001","DOIUrl":"https://doi.org/10.3960/jslrt.23001","url":null,"abstract":"<p><p>We retrospectively evaluated long-term outcomes of high dose chemotherapy followed by autologous stem cell transplant (HDC/ASCT) in patients with diffuse large B-cell lymphoma (DLBCL). Between 2004 and 2020, 46 DLBCL patients received HDC/ASCT in our institution, including 12 patients (26.1%), who received as an upfront setting (UFS). At a median follow-up time of 69 months (range, 2-169 months), the 5-year progression-free survival (PFS) rates were 82.5% (95%CI, 46.1-95.3%) in the UFS, and 57.8% (95%CI, 38.1-73.2%) in the relapsed or refractory (R/R) patients (n=34), respectively. The 5-year PFS rates were 62.3% (95%CI, 34.0-81.3%) in primary resistant (n=13) or early relapsing (within 1 year from the initial diagnosis) patients (n=4), and 53.3% (95%CI, 25.9-74.6%) in those relapsing >1 year after the initial diagnosis (n=17), with no statistically significant difference (p=0.498). In R/R patients, multivariate analysis showed that the remission status before HDC/ASCT was an independent poor prognostic factor for progression-free survival (hazard ratio [HR], 17.0; 95%CI, 3.35-86.6; p=0.000630) and high-risk category in the international prognostic index for OS (HR, 9.39; 95%CI, 1.71-51.6; p=0.0100). The incidence of non-relapse mortality by 5 years, and 10 years were 12.2%, and 15.2%, respectively. Eleven patients (23.9%) developed second malignancies, which was the most frequent late complication after HDC/ASCT, with 5-year, and 10-year cumulative incidence of 16.9%, 22.5%, respectively. In conclusion, HDC/ASCT is effective for chemo-sensitive R/R DLBCL regardless of the timing and lines of therapy. However, careful observation is required, considering the long-term complications such as secondary malignancies.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/84/jslrt-63-99.PMC10410619.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10322875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of TGF-beta1 and TNF-alpha1 produced by neoplastic cells in the pathogenesis of fibrosis in patients with hematologic neoplasms.","authors":"Haruko Takizawa,&nbsp;Yoshihiko Araki,&nbsp;Maki Fujishiro,&nbsp;Shigeki Tomita,&nbsp;Satsuki Kishikawa,&nbsp;Akane Hashizume,&nbsp;Toru Mitsumori,&nbsp;Hideaki Nitta,&nbsp;Hiroko Iizuka-Honma,&nbsp;Tomohiro Sawada,&nbsp;Mitsuo Okubo,&nbsp;Yasunobu Sekiguchi,&nbsp;Miki Ando,&nbsp;Masaaki Noguchi","doi":"10.3960/jslrt.22044","DOIUrl":"https://doi.org/10.3960/jslrt.22044","url":null,"abstract":"<p><p>We conducted this study with the objective of elucidating the mechanism of development of fibrosis in hematologic neoplasms and develop treatments for these patients. Among the suggested mechanisms of development of fibrosis is cases of hematologic neoplasms is the production of TGF-beta1 (transforming growth factor-beta-1) and TNF-alpha1 (tumor necrotizing factor-alpha-1) by the tumor cells, both of which are fibrosis-stimulating cytokines that act on fibroblasts to promote fibrosis. However, there are few reports based on human clinical pathology studies. We conducted an immunohistochemical study on paraffin-embedded formalin-fixed specimens obtained from 104 patients with various pathologic conditions (acute leukemia, malignant lymphoma, inflammation, cancer, etc.). The association of tissue fibrosis with positive immunohistochemistry for TGF- beta1 and/or TNF-alpha1, TGF-beta1 was found to be strongly associated with tissue fibrosis, and in cases with positive immunohistochemistry for TGF-beta1, the odds ratio for fibrosis was 12.8, which was significantly high. Combined positivity for TGF-beta1 and TNF-alpha1 was also associated with a significant odds ratio for fibrosis of 3.4, suggesting that TGF-beta1 expression is an important prerequisite. TGF-beta1 has been suggested as playing a relatively important role in tissue fibrosis. Future clinical application of these cytokines for both diagnosis and treatment is expected.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/6b/jslrt-63-83.PMC10410624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10322876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}